compounded semaglutide fda warning november 2025 Shares Safety Data About 'Adverse Events' From Weight Loss Drugs Congress Introduces SAFE Drugs Act

No hair loss

First, injectable users (compounded semaglutide and especially compounded tirzepatide) report the strongest satisfaction and the most consistent weight-loss numbers

Developed by Eli Lilly, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors a mechanism that may offer advantages for weight management, metabolic health, and conditions such as polycystic ovary syndrome (PCOS) that disproportionately affect women

Shima Hadidchi MD Family Practice is to support patients in achieving their weight-loss objectives safely and effectively, utilizing evidence-based treatments such as GLP-1 receptor agonists, alongside personalized lifestyle counseling and ongoing clinical support